Vitruvias Therapeutics Recalls 30mg Thyroid Tablets Nationwide Over Super-Potency Risk

On August 21, 2026, the Food and Drug Administration announced a nationwide recall of a single lot of 30-milligram thyroid tablets manufactured by Vitruvias Therapeutics. The regulatory action was triggered after routine testing revealed the tablets may contain a higher dose of the active ingredient than indicated on the label, a condition the agency formally classified as "potential super potency."[1]

The affected medication is packaged in 100-count bottles and was distributed to wholesalers and pharmacies across the United States. Patients can identify the recalled product by checking the manufacturer label for lot number 11534A, which carries an expiration date of April 2027. No other lots or dosages from the manufacturer are currently included in this specific safety alert.[1][5]

Thyroid tablets are prescribed to treat hypothyroidism, a condition where the thyroid gland does not produce enough hormones to regulate the body's energy use. When a patient ingests a super-potent tablet, they face the immediate risk of drug-induced hyperthyroidism, an overactive thyroid state that artificially and rapidly accelerates the body's metabolism.[3][6]

The FDA warns that sudden hyperthyroidism can manifest through severe cardiac symptoms, including irregular heartbeats, a rapid pulse, and elevated blood pressure. Patients might also experience unexplained weight loss, excessive sweating, muscle weakness, and heightened anxiety shortly after consuming the elevated dosage.[1][2]

This excessive dosage warning carries acute risks for older adults and individuals with underlying cardiovascular conditions. For these vulnerable populations, a sudden spike in thyroid hormone levels can precipitate cardiac arrhythmias or exacerbate existing heart disease, potentially requiring immediate medical intervention to stabilize their heart rate.[2][4]

Vitruvias Therapeutics initiated the voluntary recall immediately after the potency discrepancy was discovered during standard quality control checks. By August 26, 2026, the company had instructed all distributors and retail pharmacies to immediately quarantine the affected 100-count bottles and halt any further dispensing to patients.[1]

The recall highlights the narrow therapeutic index of thyroid drugs, a class of medications where even minor dosage variations can significantly impact patient health. Industry watchdogs note that maintaining exact potency in thyroid formulations is notoriously difficult, making strict adherence to manufacturing standards critical for patient safety.[6]

Healthcare providers emphasize that patients should not abruptly stop taking their thyroid medication without medical supervision, even if they possess the recalled lot. On August 27, 2026, Jackson Health System advised patients to contact their prescribing physician or pharmacist immediately to arrange for a safe, standard-potency replacement.[3][5]

Consumers who have experienced adverse reactions are instructed to report their symptoms to the FDA's MedWatch Adverse Event Reporting program. Pharmacies are currently processing returns for the recalled bottles, ensuring patients can seamlessly transition to a verified lot and continue their daily treatment regimen without interruption.[1][4]